You are hereHome CategoriesJordan
Tabuk Pharmaceuticals signs license and supply agreement with Selectchemie
Source: PRNewswire , Author: Posted by BI-ME staff
Posted: Fri October 6, 2017 11:56 am

JORDAN. -- /PRNewswire/ -- Tabuk Pharmaceutical Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa (MENA) region, has entered into an agreement with Selectchemie, under which Selectchemie granted Tabuk a license to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle East.

Selectchemie is one of the leading European companies, headquartered in Zurich serving the pharmaceutical and human nutrition industries since 1969 as a premier supplier of high quality ingredients.

Dr. Rana Azzam, Senior VP of Business Development said "We are excited about this major partnership collaboration with Selectchemie. Caspofungin Injection is a hard to develop and lifesaving product. This partnership will provide an opportunity for both companies to leverage their combined strength."

Selectchemie side commented "Dr. Peter Kaufmann, CEO of Selectchemie, is proud to have gained Tabuk Pharmaceutical Manufacturing Company as a licensing and marketing partner for Caspofungin in the MENA Region. With this highest quality product, manufactured in Europe, Selectchemie looks forward to a long-term partnership with Tabuk to the benefit of both companies and end-users."

 

MIDDLE EAST BUSINESS COMMENT & ANALYSIS

date:Posted: June 22, 2018
Bain & Company's spring luxury update highlights four trends shaping the personal luxury goods market in 2018 and beyond.
date:Posted: June 21, 2018
INTERNATIONAL. Private sector can be an important partner in meeting US$320 billion in oil and gas investment, Crescent Petroleum CEO tells OPEC seminar.
date:Posted: June 18, 2018
UAE. 24% of Middle Eastern entrepreneurs are motivated by social impact and view it as their top priority as a business owner; 66% are undertaking angel investing.
dhgate